Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩8,710, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 48% over the past three years. Buy Or Sell Opportunity • May 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to ₩11,440. The fair value is estimated to be ₩14,547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 12%. Buy Or Sell Opportunity • Apr 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.8% to ₩14,280. The fair value is estimated to be ₩18,141, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has grown by 13%. 공고 • Mar 04
BIO-FD&C Co.,Ltd., Annual General Meeting, Mar 30, 2026 BIO-FD&C Co.,Ltd., Annual General Meeting, Mar 30, 2026, at 11:00 Tokyo Standard Time. Location: seminar room, 98, sandan-gil, hwasun-eup, hwasun-gun, jeollanam-do, South Korea Reported Earnings • Nov 14
Third quarter 2025 earnings released: EPS: ₩227 (vs ₩125 in 3Q 2024) Third quarter 2025 results: EPS: ₩227 (up from ₩125 in 3Q 2024). Revenue: ₩5.07b (up 41% from 3Q 2024). Net income: ₩1.94b (up 82% from 3Q 2024). Profit margin: 38% (up from 30% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Oct 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩141.6b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Sep 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to ₩18,300. The fair value is estimated to be ₩23,054, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.8% over the last 3 years. Earnings per share has grown by 10%. Buy Or Sell Opportunity • Aug 20
Now 21% undervalued Over the last 90 days, the stock has risen 12% to ₩18,240. The fair value is estimated to be ₩23,054, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.8% over the last 3 years. Earnings per share has grown by 10%. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩21,450, the stock trades at a trailing P/E ratio of 36.9x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 9.5% over the past three years. Buy Or Sell Opportunity • May 21
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to ₩15,880. The fair value is estimated to be ₩12,988, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Earnings per share has grown by 15%. 공고 • Feb 27
BIO-FD&C Co.,Ltd., Annual General Meeting, Mar 31, 2025 BIO-FD&C Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: seminar room, 30, songdomirae-ro, yeonsu-gu, incheon South Korea Buy Or Sell Opportunity • Jan 15
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to ₩13,780. The fair value is estimated to be ₩17,406, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 20%. Buy Or Sell Opportunity • Dec 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.7% to ₩13,900. The fair value is estimated to be ₩17,390, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.5% over the last 3 years. Earnings per share has grown by 20%. Reported Earnings • Nov 14
Third quarter 2024 earnings released: EPS: ₩125 (vs ₩134 in 3Q 2023) Third quarter 2024 results: EPS: ₩125 (down from ₩134 in 3Q 2023). Revenue: ₩3.60b (down 8.4% from 3Q 2023). Net income: ₩1.07b (down 6.5% from 3Q 2023). Profit margin: 30% (in line with 3Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 36% growth forecast for the Biotechs industry in South Korea. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩17,740, the stock trades at a trailing P/E ratio of 29.9x. Average forward P/E is 23x in the Biotechs industry in South Korea. Total returns to shareholders of 37% over the past year. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩13,880, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 5.9% over the past year. Buy Or Sell Opportunity • Jul 11
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to ₩15,320. The fair value is estimated to be ₩12,751, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last year. Earnings per share has grown by 15%. Buy Or Sell Opportunity • Jul 01
Now 16% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to ₩14,990. The fair value is estimated to be ₩12,918, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last year. Earnings per share has grown by 15%. Buy Or Sell Opportunity • Jun 26
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 25% to ₩15,800. The fair value is estimated to be ₩12,859, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last year. Earnings per share has grown by 15%. Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩134 (vs ₩87.00 in 3Q 2022) Third quarter 2023 results: EPS: ₩134 (up from ₩87.00 in 3Q 2022). Revenue: ₩3.93b (up 32% from 3Q 2022). Net income: ₩1.14b (up 51% from 3Q 2022). Profit margin: 29% (up from 25% in 3Q 2022). The increase in margin was driven by higher revenue. Buying Opportunity • Sep 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be ₩18,386, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Earnings per share has grown by 4.2%. New Risk • Sep 13
New major risk - Revenue and earnings growth Revenue has declined by 12% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 12% over the past year. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩132.3b market cap, or US$99.7m). New Risk • Jul 25
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩127.5b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩127.5b market cap, or US$99.6m). 공고 • Oct 19
BIO-FD&C Co.,Ltd. (KOSDAQ:A251120) announces an Equity Buyback for KRW 3,000 million worth of its shares. BIO-FD&C Co.,Ltd. announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with DB Financial Investment Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on April 18, 2023. As of October 19, 2022, the company had 0 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₩15,600, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 21x in the Biotechs industry in South Korea.